Patents Represented by Attorney, Agent or Law Firm Charles E. Dadswell
  • Patent number: 5559235
    Abstract: The present invention relates to water soluble, camptothecin derivatives of formula (I), ##STR1## wherein: 1) R.sup.1 and R.sup.2 represent independently, hydrogen, lower alkyl, C.sub.3-7)cycloalkyl, C.sub.3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, lower alkoxy lower alkyl;ii) R.sup.1 represents hydrogen, lower alkyl, C.sub.3-7)cycloalkyl, C.sub.3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl or lower alkoxy lower alkyl, and R.sup.2 represents --COR.sup.3,wherein:R.sup.3 represents hydrogen, lower alkyl, perhalo-lower alkyl, C.sub.3-7)cycloalkyl, C.sub.3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, lower alkoxy or lower alkoxy lower alkyl; oriii) R.sup.1 and R.sup.2 taken together with the linking nitrogen form a saturated 3 to 7 atom heterocyclic group of formula (IA) ##STR2## wherein: Y represents O, S, SO, SO.sub.2, CH.sub.2 or NR.sup.4wherein:R.sup.
    Type: Grant
    Filed: June 10, 1994
    Date of Patent: September 24, 1996
    Assignee: Glaxo Wellcome Inc.
    Inventors: Michael J. Luzzio, Jeffrey M. Besterman, Michael G. Evans, Peter L. Myers
  • Patent number: 5543406
    Abstract: The present invention relates to certain substituted 17.beta.-substituted carbonyl-6-azaandrost-4-en-3-ones of formula (I), especially those of formula (IG) ##STR1## wherein R.sup.1 and R.sup.2 arei) independently hydrogen or lower alkyl and the bond between the carbons bearing R.sup.1 and R.sup.2 is a single or a double bond, orii) taken together are a --CH.sub.2 -- group to form a cyclopropane ring, and the bond between the carbons bearing R.sup.1 and R.sup.2 is a single bond;R.sup.3c is hydrogen;R.sup.4c is hydrogen, lower alkyl, lower cycloalkyl, lower alkenyl, alkanoyl of 2-6 carbons, --(CH.sub.2).sub.m CO.sub.2 R.sup.16, --(CH.sub.2).sub.m Ar.sup.a, --(CH.sub.2).sub.n 'CONR.sup.17 R.sup.18, --(CH.sub.2).sub.n 'NR.sup.17 R.sup.18 or --(CH.sub.2).sub.n 'OR.sup.16, wherein R.sup.16 is hydrogen, lower alkyl or lower alkenyl; R.sup.17 and R.sup.18 are independently hydrogen, lower alkyl lower cycloalkyl or lower alkenyl; Ar.sup.
    Type: Grant
    Filed: August 15, 1994
    Date of Patent: August 6, 1996
    Assignee: Glaxo Wellcome, Inc.
    Inventors: Robert C. Andrews, Cynthia M. Cribbs, Stephen V. Frye, Curt D. Haffner, Patrick R. Maloney
  • Patent number: 5541322
    Abstract: A process of providing novel compounds of Formula (I), that are useful as 6-azaandrostenone testosterone 5-alpha-reductase inhibitors, from commercially available compounds of Formula (II) ##STR1## wherein the substituents are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof.
    Type: Grant
    Filed: October 14, 1994
    Date of Patent: July 30, 1996
    Assignee: Glaxo Wellcome Inc.
    Inventors: Francis G. Fang, Matthew J. Sharp
  • Patent number: 5508432
    Abstract: CCK modulators, e.g. agonists or antagonists, of the following formula (I): ##STR1## or a base-addtion salt thereof.
    Type: Grant
    Filed: June 8, 1994
    Date of Patent: April 16, 1996
    Assignee: Glaxo Wellcome Inc.
    Inventors: Elizabeth E. Sugg, Milana Dezube, Gavin C. Hirst
  • Patent number: 5491237
    Abstract: A process of providing novel compounds of Formula (I) below, which are useful as intermediates in the preparation of camptothecin and camptothecin-like compounds, ##STR1## wherein: R.sup.1 represents alkyl, particularly methyl, R.sup.2 represents H or alkyl, particularly methyl, R3 represents H or alkyl, particularly H; Q represents triflate or halo particularly bromo and iodo more particularly iodo and Y represents H, chloro or OR.sup.4, wherein R.sup.4 represents alkyl or triflate, or particularly H.
    Type: Grant
    Filed: May 3, 1994
    Date of Patent: February 13, 1996
    Assignee: Glaxo Wellcome Inc.
    Inventors: Francis G. Fang, Melissa W. Lowery, Shiping Xie
  • Patent number: 5426196
    Abstract: The present Invention includes synthetic steps and intermediates involved in the following reaction scheme a of converting compounds of Formula (II) to the diarylmethanes of Formula (I): ##STR1## wherein: Y is oxygen or sulfur;A, B, C, D, and E are carbon or 1, 2 or 3 of A, B, C, D, and E are independently nitrogen, and the others are carbon; andwhereinR.sup.1 through R.sup.10 are selected independently from the group consisting of: hydrogen, hydroxy, alkyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.3 -C.sub.8 cycloalkyl alkyl, alkenyl, hydroxy alkyl, alkoxy alkyl, perhalo-alkyl, amino, nitro, nitrile, halo, carboxyl, sulfonyl, acyl, formyl, carbamoyl, trifluoromethyl, aminomethyl, azido, amido, hydrazino, aryl, aryloxy, heteroaryl, or aryl or heteroaryl, mono, di, or tri substituted with one or more hydrogen, hydroxy, alkyl, C.sub.3 -C.sub.8 cycloalkyl, C.sub.3 -C.sub.
    Type: Grant
    Filed: December 22, 1993
    Date of Patent: June 20, 1995
    Assignee: Glaxo Inc.
    Inventor: Francis G. Fang
  • Patent number: 5421492
    Abstract: The present invention relates to an aerosol dispensing apparatus, more particularly to aerosol dispensing valves incorporating a controlled metered dispensing function wherein the metering chamber holding the next aerosolized dose is in fluidic communication with the reservoir allowing homogenous mixing of the next aerosolized dose to be dispensed.
    Type: Grant
    Filed: November 2, 1993
    Date of Patent: June 6, 1995
    Assignee: Glaxo Inc.
    Inventors: Lee A. Barger, Terence G. H. Bowyer, Ignatius L. Britto, Michael L. Franklin
  • Patent number: 5213790
    Abstract: Compositions for/methods of reducing plaque and gingivitis with reduced staining.
    Type: Grant
    Filed: October 23, 1991
    Date of Patent: May 25, 1993
    Assignee: The Procter & Gamble Co.
    Inventors: Michael F. Lukacovic, Satyanarayana Majeti